Cell encapsulation technology as a therapeutic strategy for CNS malignancies

Area of Science:

• Biotechnology
• Oncology
• Biomaterials Science

Background:

• Gene therapy via viral vectors has shown limited clinical success.
• Cell encapsulation provides a nonviral alternative for delivering therapeutic agents to tumors.
• This approach utilizes genetically engineered cells within protective capsules for localized treatment.

Purpose of the Study:

• To explore cell encapsulation as a viable strategy for localized tumor treatment.
• To highlight the potential of encapsulated cells as "bioreactors" for sustained therapeutic protein delivery.
• To discuss the application of this technology in treating central nervous system malignancies, such as gliomas.

Main Methods:

• Genetically engineered producer cells secreting therapeutic proteins are encapsulated in immunoisolating materials.
• Macro- and microencapsulation techniques are employed, with alginate being a common material.
• Encapsulated cells (bioreactors) are designed for transplantation and controlled release of recombinant proteins.

Main Results:

• Cell encapsulation technology has advanced significantly, with successful implantation in animal and human studies.
• Alginate encapsulation is well-tolerated and suitable for various tissues, including the brain.
• Bioreactors can be implanted in the brain for local, sustained drug delivery to target tumor recurrence sites.

Conclusions:

• Cell encapsulation is a versatile, nonviral platform for localized cancer therapy, especially for CNS tumors.
• Integration with tumor genomics and proteomics can optimize bioreactor design and therapeutic protein selection.
• This approach holds significant potential for improving treatment outcomes in oncology.